Novartis Cosentyx sets the new benchmark in psoriasis with robust 5year sustained efficacy and safety Phase III data

EAST HANOVER N.J. Sept. 13 2017 PRNewswire Novartis announced today first of its kind Phase III data showing Cosentyx secukinumab delivered high and longlasting skin clearance in patients with moderate to severe plaque psoriasis at 5 years.1 These data w...